Aptorum Group Limited (APM)
| Market Cap | 93.99M |
| Revenue (ttm) | 911,509 |
| Net Income (ttm) | 6.31M |
| Shares Out | 13.16M |
| EPS (ttm) | 0.20 |
| PE Ratio | 13.20 |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 23 |
| Last Price | $2.64 |
| Previous Close | $2.75 |
| Change ($) | -0.11 |
| Change (%) | -4.00% |
| Day's Open | 2.79 |
| Day's Range | 2.58 - 2.80 |
| Day's Volume | 113,555 |
| 52-Week Range | 1.16 - 14.23 |
Aptorum Group Limited (NASDAQ: APM) announces further interim data from its ongoing Phase 1 trial for ALS-4 targeting Staphylococcus aureus. Specifically, two additional cohorts (Cohort C & D) of the s...
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #MRSA--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, ...
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #biopharmaceutical--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM), a clinical-stage biopharmaceutical company focused on the deve...
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #biopharmaceutical--Aptorum Group Limited (NASDAQ: APM, Euronext Paris: APM) (“Aptorum Group”, the “Company”), a clinical-stage biopharmaceutical company foc...
Which Reddit penny stocks are investors watching right now? Check these 3 out The post 3 Penny Stocks on Reddit Making Big Waves Right Now appeared first on Penny Stocks to Buy, Picks, News and Informat...
Aptorum Group Limited (NASDAQ: APM) has completed two initial cohorts of the single-dose ascending dose (SAD) portion of the Phase 1 trial evaluating ALS-4 small molecule targeting Staphylococcus aureus...
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #biopharmaceutical--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceuti...
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #biopharmaceutical--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceuti...
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #biopharmaceutical--Regulatory News: Aptorum Group Limited (Nasdaq: APM), a clinical-stage biopharmaceutical company dedicated to meeting unmet medical needs...
Aptorum Shares Are Trading Higher On Immunomodulators Agreement For Autoimmune, Oncology Indications
Aptorum Group Ltd (NASDAQ: APM) has entered into a material transfer and option agreement with Yale University to evaluate a group of preclinical stage novel immunomodulators. Aptorum also obtained an e...
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #autoimmune--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical com...
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #MRSA--Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncol...
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #MRSA--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a biopharmaceutical company focused on novel...
Aptorum (APM) stock is on the rise Wednesday after announcing approval to move forward with a clinical trial of its staph infection drug. The post APM Stock: 9 Things to Know About Aptorum as Shares Fly...
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #biopharmaceutical--Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ) (“Aptorum Group” or “Aptorum”), a biopharmaceutical company focused on novel t...
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #CTAsubmission--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a biopharmaceutical company focused...
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #biopharmaceutical--Regulatory News: Aptorum Group Limited (Nasdaq: APM; Euronext Paris: APM) (the “Company”, “Aptorum Group” or “Aptorum”), a biopharmaceuti...
Aptorum Group has competition in the rapid pathogen identification and detection diagnostics (RPIDD) field. Is APM stock the best bet?
Aptorum Group got a boost when the company jumped into the Covid-19 conversation. APM stock looks like a late entry into crowded field.
APM stock is a risky name, but the company's recent deal with Singapore has potentially given it a huge opportunity in Asia. The post Why Aptorum's New Singapore Deal Makes It a Worthwhile Buy appeared ...
APM stock remains a highly speculative bet for investors as the small biotech company comes with significant risk and volatility. The post Aptorum Group Is Risky, Despite Popularity appeared first on In...
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #biopharmaceutical--Regulatory News: Aptorum Group Limited (Nasdaq: APM; Euronext Paris: APM) (the “Company”, “Aptorum Group” or “Aptorum”), a biopharmaceuti...
APM stock mostly flew under the radar among biotechnology investors. After a recent price surge, though, the stock is now an attention getter.
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #biopharmaceutical--Aptorum Group Limited (Nasdaq:APM, Euronext Paris:APM) (“Aptorum Group” or “Aptorum”), a biopharmaceutical company focused on novel techn...
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #biopharmaceutical--Regulatory News: Aptorum Group Limited (Nasdaq:APM, Euronext Paris:APM) (“Aptorum Group” or “Aptorum”), a biopharmaceutical company focus...
Aptorum Group Ltd. (NASDAQ: APM) shares absolutely exploded on Tuesday after the company announced that it would be launching a subsidiary focused on novel technologies targeting infectious diseases. Al...
Aptorum Group Ltd (NASDAQ: APM) shares are skyrocketing Tuesday following an announcement concerning the setting up of a subsidiary focused on diagnostic testing. What Happened: U.K.-based Aptorum th...
APM stock is soaring on news that Aptorum Group is launching a subsidiary focused on liquid biopsies for infectious diseases. The post APM Stock: Why Aptorum Group Is Soaring 500% Today appeared first ...
NEW YORK, LONDON, & PARIS--(BUSINESS WIRE)-- #biopharmaceutical--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ) (“Aptorum Group” or “Aptorum”), a biopharmaceutical company f...
NEW YORK--(BUSINESS WIRE)-- #biopharmaceutical--Regulatory News: Aptorum Group Limited (NASDAQ: APM), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet...
NEW YORK--(BUSINESS WIRE)-- #euronextlisting--Regulatory News: Aptorum Group Limited (Nasdaq:APM) (“Aptorum Group”), a biopharmaceutical company focusing on the development of novel therapeutics to addr...
NEW YORK--(BUSINESS WIRE)-- #Euronext--Regulatory News: Aptorum Group Limited (Nasdaq:APM) (“Aptorum Group”), a biopharmaceutical company focusing on the development of novel therapeutics to address glo...
About APM
Aptorum Group Limited, a pharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of diseases with a focus on infectious diseases and cancers. Its pipeline enables the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health... [Read more...]
| Industry Biotechnology | IPO Date Dec 18, 2018 |
| Stock Exchange NASDAQ | Ticker Symbol APM |
Analyst Forecasts
According to 2 analysts, the average rating for Aptorum Group stock is "Strong Buy." The 12-month stock price forecast is 13.00, which is an increase of 392.42% from the latest price.